GB0215526D0 - Anticancer compounds - Google Patents

Anticancer compounds

Info

Publication number
GB0215526D0
GB0215526D0 GBGB0215526.5A GB0215526A GB0215526D0 GB 0215526 D0 GB0215526 D0 GB 0215526D0 GB 0215526 A GB0215526 A GB 0215526A GB 0215526 D0 GB0215526 D0 GB 0215526D0
Authority
GB
United Kingdom
Prior art keywords
anticancer compounds
compounds
formula
anticancer
ruthenium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0215526.5A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Edinburgh
Original Assignee
University of Edinburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Edinburgh filed Critical University of Edinburgh
Priority to GBGB0215526.5A priority Critical patent/GB0215526D0/en
Publication of GB0215526D0 publication Critical patent/GB0215526D0/en
Priority to JP2004518958A priority patent/JP2005536487A/en
Priority to AU2003251159A priority patent/AU2003251159B2/en
Priority to DE60323529T priority patent/DE60323529D1/en
Priority to DK03762788T priority patent/DK1558620T3/en
Priority to PCT/GB2003/002879 priority patent/WO2004005304A1/en
Priority to EP03762788A priority patent/EP1558620B1/en
Priority to CA002491640A priority patent/CA2491640A1/en
Priority to PT03762788T priority patent/PT1558620E/en
Priority to ES03762788T priority patent/ES2314245T3/en
Priority to MXPA05000314A priority patent/MXPA05000314A/en
Priority to BR0312470-3A priority patent/BR0312470A/en
Priority to PL03373049A priority patent/PL373049A1/en
Priority to NZ538005A priority patent/NZ538005A/en
Priority to CNB038160005A priority patent/CN100362005C/en
Priority to KR1020057000143A priority patent/KR20050053589A/en
Priority to AT03762788T priority patent/ATE407937T1/en
Priority to US10/520,239 priority patent/US20060058270A1/en
Priority to ZA200500908A priority patent/ZA200500908B/en
Priority to NO20050640A priority patent/NO20050640L/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F17/00—Metallocenes
    • C07F17/02—Metallocenes of metals of Groups 8, 9 or 10 of the Periodic System
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Ruthenium (II) compounds of formula (I) are useful in the treatment and/or prevention of cancer, wherein formula (I) is:
GBGB0215526.5A 2002-07-05 2002-07-05 Anticancer compounds Ceased GB0215526D0 (en)

Priority Applications (20)

Application Number Priority Date Filing Date Title
GBGB0215526.5A GB0215526D0 (en) 2002-07-05 2002-07-05 Anticancer compounds
US10/520,239 US20060058270A1 (en) 2002-07-05 2003-07-04 Ruthenium anticancer complexes
PT03762788T PT1558620E (en) 2002-07-05 2003-07-04 Ruthenium anticancer complexes
MXPA05000314A MXPA05000314A (en) 2002-07-05 2003-07-04 Ruthenium anticancer complexes.
DE60323529T DE60323529D1 (en) 2002-07-05 2003-07-04 Ruthenium complexes with anti-cancer effects
DK03762788T DK1558620T3 (en) 2002-07-05 2003-07-04 Ruthenium complexes with anticancer effect
PCT/GB2003/002879 WO2004005304A1 (en) 2002-07-05 2003-07-04 Ruthenium anticancer complexes
EP03762788A EP1558620B1 (en) 2002-07-05 2003-07-04 Ruthenium anticancer complexes
CA002491640A CA2491640A1 (en) 2002-07-05 2003-07-04 Ruthenium anticancer complexes
JP2004518958A JP2005536487A (en) 2002-07-05 2003-07-04 Ruthenium anticancer complex
ES03762788T ES2314245T3 (en) 2002-07-05 2003-07-04 ANTICANCER RUTENIUM COMPLEXES.
AU2003251159A AU2003251159B2 (en) 2002-07-05 2003-07-04 Ruthenium anticancer complexes
BR0312470-3A BR0312470A (en) 2002-07-05 2003-07-04 Compound, use thereof, pharmaceutical composition, method of treating and / or preventing cancer, and process for preparing the compound
PL03373049A PL373049A1 (en) 2002-07-05 2003-07-04 Ruthenium anticancer complexes
NZ538005A NZ538005A (en) 2002-07-05 2003-07-04 Ruthenium anticancer complexes
CNB038160005A CN100362005C (en) 2002-07-05 2003-07-04 Ruthenium anticancer complexes
KR1020057000143A KR20050053589A (en) 2002-07-05 2003-07-04 Ruthenium anticancer complexes
AT03762788T ATE407937T1 (en) 2002-07-05 2003-07-04 RUTHENIUM COMPLEXES WITH ANTI-CANCER EFFECT
ZA200500908A ZA200500908B (en) 2002-07-05 2005-02-01 Ruthenium anticancer complexes
NO20050640A NO20050640L (en) 2002-07-05 2005-02-04 Ruthenium anticancer complexes

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0215526.5A GB0215526D0 (en) 2002-07-05 2002-07-05 Anticancer compounds

Publications (1)

Publication Number Publication Date
GB0215526D0 true GB0215526D0 (en) 2002-08-14

Family

ID=9939861

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0215526.5A Ceased GB0215526D0 (en) 2002-07-05 2002-07-05 Anticancer compounds

Country Status (20)

Country Link
US (1) US20060058270A1 (en)
EP (1) EP1558620B1 (en)
JP (1) JP2005536487A (en)
KR (1) KR20050053589A (en)
CN (1) CN100362005C (en)
AT (1) ATE407937T1 (en)
AU (1) AU2003251159B2 (en)
BR (1) BR0312470A (en)
CA (1) CA2491640A1 (en)
DE (1) DE60323529D1 (en)
DK (1) DK1558620T3 (en)
ES (1) ES2314245T3 (en)
GB (1) GB0215526D0 (en)
MX (1) MXPA05000314A (en)
NO (1) NO20050640L (en)
NZ (1) NZ538005A (en)
PL (1) PL373049A1 (en)
PT (1) PT1558620E (en)
WO (1) WO2004005304A1 (en)
ZA (1) ZA200500908B (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE303393T1 (en) * 1999-10-27 2005-09-15 Univ Court The University Of E HALF SANDWICH RUTHENIUM(II) COMPOUNDS WITH A NITROGEN CONTAINING LIGAND FOR CANCER THERAPY
JP2006525982A (en) 2003-04-30 2006-11-16 ザ ユニバーシティ コート オブ ザ ユニバーシティ オブ エジンバラ Ruthenium (II) complexes for treating tumors
GB0418643D0 (en) * 2004-08-20 2004-09-22 Univ Edinburgh Ruthenium (II) compounds
GB0604602D0 (en) * 2006-03-07 2006-04-19 Univ Edinburgh Ruthenium (II) compounds
EP2016085B9 (en) * 2006-05-09 2015-12-30 Ecole Polytechnique Fédérale de Lausanne (EPFL) Transition metal complexes for inhibiting resistance in the treatment of cancer and metastasis
GB0610062D0 (en) * 2006-05-19 2006-06-28 Univ Edinburgh Ruthenium (ll) compounds
DE102009053392A1 (en) * 2009-11-14 2011-06-22 Umicore AG & Co. KG, 63457 Process for the preparation of Ru (0) olefin complexes
WO2013038395A1 (en) 2011-09-16 2013-03-21 Universidade De Lisboa Transition metal complexes for pharmaceutical applications
WO2013136296A2 (en) 2012-03-14 2013-09-19 Universidade De Lisboa Water-soluble organometallic ruthenium and iron compunds presenting heteroaromatic ligands
CN103360428A (en) * 2012-04-09 2013-10-23 中国科学院化学研究所 Ruthenium-containing complex for inhibiting protein tyrosine phosphatase 1B activity as well as preparation method of complex and protein tyrosine phosphatase 1B inhibitor
CN102964385B (en) * 2012-11-30 2015-02-18 广西师范学院 Organic metal ruthenium compound and preparation method and application thereof
US9751081B2 (en) 2014-12-01 2017-09-05 Clemson University Self-regenerating antioxidant catalysts and methods of using the same

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4980473A (en) * 1985-01-18 1990-12-25 The Trustees Of Columbia University In The City Of New York Chemical probes for left-handed DNA and chiral metal complexes as Z-specific anti-tumor agents
EP1300381B1 (en) * 1995-12-06 2006-03-08 Japan Science and Technology Agency Process for preparing optically active alcohols
ATE303393T1 (en) * 1999-10-27 2005-09-15 Univ Court The University Of E HALF SANDWICH RUTHENIUM(II) COMPOUNDS WITH A NITROGEN CONTAINING LIGAND FOR CANCER THERAPY
GB0016052D0 (en) * 2000-06-30 2000-08-23 Univ Edinburgh Ruthenium (II) compounds

Also Published As

Publication number Publication date
ES2314245T3 (en) 2009-03-16
PL373049A1 (en) 2005-08-08
CN100362005C (en) 2008-01-16
EP1558620B1 (en) 2008-09-10
AU2003251159B2 (en) 2008-11-06
US20060058270A1 (en) 2006-03-16
CA2491640A1 (en) 2004-01-15
AU2003251159A1 (en) 2004-01-23
EP1558620A1 (en) 2005-08-03
BR0312470A (en) 2005-04-26
ATE407937T1 (en) 2008-09-15
CN1665826A (en) 2005-09-07
DE60323529D1 (en) 2008-10-23
WO2004005304A1 (en) 2004-01-15
ZA200500908B (en) 2006-03-29
NO20050640L (en) 2005-03-22
NZ538005A (en) 2007-08-31
JP2005536487A (en) 2005-12-02
PT1558620E (en) 2008-12-03
MXPA05000314A (en) 2005-09-20
KR20050053589A (en) 2005-06-08
DK1558620T3 (en) 2009-01-05

Similar Documents

Publication Publication Date Title
ZA200500908B (en) Ruthenium anticancer complexes
TW200510325A (en) 2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof
RS50939B (en) 2-phenyl benzimidazoles and imidazo-/4,5/-pyridines as cdsi/chk2-inhibitors and adjuvants to chemotherapy or radiation therapy in the treatment of cancer
PT1420801E (en) Use of fucans in the treatment of adhesions, arthritis and psoriasis
AU2795000A (en) Epothilone derivatives and their use as antitumor agents
IL164509A0 (en) Furyl compounds
RS20050070A (en) Use of 1kb kinase inhibitors for the treatment of pain
WO2003106384A3 (en) Novel boronic chalcone derivatives and uses thereof
WO2003106450A8 (en) Phenylaminopyrimidines and their use as rho-kinase inhibitors
PT1390371E (en) OXAZOLO- AND FUROPYRIMIDINES AND THEIR USE IN MEDICINES AGAINST TUMORS
AU2003212634A1 (en) Compounds useful in the treatment of cancer
WO2005030794A3 (en) Hemiasterlin derivatives and uses thereof
EP1551388A4 (en) Compounds useful for the treatment of cancer, compositions thereof and methods therewith
MXPA02012911A (en) Ruthenium (ii) compounds for use in the therapy of cancer.
HK1084954A1 (en) Ruthenium(II) complexes for the treatment of tumors
MXPA06000372A (en) Silicon compounds and their use.
MX2008001548A (en) Antitumoral compounds.
GB0015446D0 (en) Combined therapy against tumors comprising substituted acryloyl distamycin derivates,taxanes and/or antimetabolites
TW200603801A (en) Novel dialkoxy-imidazopyridines
DE60220504D1 (en) Tryptasehemmer
HK1082727A1 (en) 2" oxo-voruscharin and derivatives thereof
GB0205327D0 (en) compounds
TW200613301A (en) Novel amino-halogen-imidazopyridines
WO2004089300A3 (en) Sapphyrins and uses thereof
SI1358182T1 (en) Diazocine derivates and their use as tryptase inhibitors

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)